Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy

Thumbnail Image
eschf_11_6_4314.pdf (638.31 KB)
Identifiers
URI: https://hdl.handle.net/10641/7734
ISSN: 2055-5822
DOI: 10.1002/ehf2.14971

Publication date

2024-12

Start date of the public exhibition period

End date of the public exhibition period

Authors

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Share
Export

Research Projects

Organizational Units

Journal Issue

Doctoral program

Description

Publisher Copyright: © 2024 Pfizer Inc. and The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Keywords

Cardiac amyloidosis, Epidemiology, Hypertrophy, Prevalence, Transthyretin amyloid cardiomyopathy, Cardiology and Cardiovascular Medicine, Journal Article, Multicenter Study, Yes, yes

Citation

the TTRACK investigators 2024, 'Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy', ESC Heart Failure, vol. 11, no. 6, pp. 4314-4324. https://doi.org/10.1002/ehf2.14971

Collections

FACULTAD DE MEDICINA